Annovis Bio Inc

NYSE ANVS

Data sourced from

and

Download Data

Annovis Bio Inc Cash Per Share 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -91.47%

Annovis Bio Inc Cash Per Share 1 year YoY Change (%) is -91.47% for the Trailing 12 Months (TTM) ending March 31, 2024, a -123.86% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Annovis Bio Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was 3.46, a -40.86% change year over year.
Annovis Bio Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was 5.85, a 399.64% change year over year.
Annovis Bio Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was 1.17, a 90.89% change year over year.
Annovis Bio Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.61, a 1,352.07% change year over year.

NYSE: ANVS

Annovis Bio Inc

CEO	Dr. Maria L. Maccecchini Ph.D.
IPO Date	Feb. 12, 2010
Location	United States
Headquarters	1055 Westlakes Drive, Berwyn, PA, United States, 19312
Employees	6
Sector	Healthcare
Industry	Biotechnology

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Key trends